“…The greatest challenge to diagnosing macroprolactinemia is that immunoassays cannot differentiate monomeric PRL from dimeric PRL, macro-PRL, or PRL fragments ( 7 , 8 , 10 , 19 , 22 ). This leads to inappropriate diagnosis of hyperprolactinemia, unnecessary pituitary imaging, and unindicated administration of dopamine agonists ( 7 , 18 , 19 , 22 ). Therefore, when immunoassays detect elevated PRL, it is essential to screen for the presence of macro-PRL ( 19 ).…”